StockpollyBeta
Get App
Popularity #432
REPL · NASDAQ · Biotechnology

Replimune Group (REPL)

Develops RPx oncolytic immunotherapies for melanoma and other solid tumors.

$13.41
vs last close+0.54 (+4.20%)

In millions of USD, except per-share figures

In millionsQ2 FY24Sep 2023Q3 FY24Dec 2023Q4 FY24Mar 2024Q1 FY25Jun 2024Q2 FY25Sep 2024Q3 FY25Dec 2024Q4 FY25Mar 2025Q1 FY26Jun 2025Q2 FY26Sep 2025Q3 FY26Dec 2025Q4 FY26Mar 2026Q1 FY27Jun 2026
Cost of revenue000000100000
Gross profit000000−100000
645759575966799084727368
Research & development494343434348555858535249
00000025026195419
General & administrative0000000000019
Other expenses15141614151803300−330
Operating income−64−57−59−57−59−66−80−90−84−72−73−68
46446054110−2
Interest income0000006003112
Interest expense122222221243
Other non-operating income00−1000−70−2−3−1−1
Income before tax−60−51−55−54−53−66−75−87−83−71−73−70
Income tax expense000001−100000
Net income from continuing operations−60−51−55−54−53−66−74−87−83−71−73−69
Other adjustments000000000000
Net income−60−51−55−54−53−66−74−87−83−71−73−70
EPS, basic−$0.90−$0.77−$0.90−$0.78−$0.68−$0.79−$0.96−$0.95−$0.90−$0.77−$0.76−$0.72
EPS, diluted−$0.90−$0.77−$0.90−$0.78−$0.68−$0.79−$0.96−$0.95−$0.90−$0.77−$0.76−$0.72
Weighted average shares, basic676761697983819292929397
Weighted average shares, diluted676761697983819292929397
EBITDA−63−55−55−56−58−65−72−89−82−68−75−66
Depreciation & amortization1131111112−31
EBIT−63−56−58−57−59−66−73−90−83−70−72−67